



OPEN ACCESS



Check for updates

Cite this as: *BMJ* 2020;371:m4232<http://dx.doi.org/10.1136/bmj.m4232>

Published: 03 November 2020

Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)

In this paper by Agarwal and colleagues (*BMJ* 2020;371:m3939, doi:, published 22 October 2020), the details for reference 22 should be: R&D Blueprint novel Coronavirus COVID-19 Therapeutic Trial Synopsis. World Health Organization; 2020 . (Accessed on 25 Aug 2020.) Also, the citation for reference 28 should appear at the end of the first paragraph of the strengths and limitations section of the discussion: “Although this approach could have affected comparability across study sites, we believe this lends the trial more generalisability, approximates real world scenarios more closely, and in the methodological spectrum of clinical trials, shifts it towards pragmatic trials.”²⁸”